Seonil Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seonil Kim has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Matheus F. Sathler
Colorado State University
10 shared publicationsRahmi Lee
Department of Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA
9 shared publicationsJessica P. Roberts
Molecular, Cellular and Integrative Neurosciences Program, Colorado State University, Fort Collins, CO 80523
7 shared publicationsEllison R. Black
Department of Biomedical Sciences Colorado State University Fort Collins Colorado USA
6 shared publicationsEvelina Bouckova
6 shared publicationsAnastasiya Zaytseva
Molecular, Cellular and Integrative Neurosciences Program, USA
5 shared publications
Latest Publications
- Open Access
- 27 September 2026
- Published by Wiley in Advanced Science
- p. e77858
Co‐activation of Selective Nicotinic Acetylcholine Receptor Subtypes Is Required for Neuroprotection against Alzheimer's Disease
Beta‐amyloid peptide (Aβ)‐induced suppression of hippocampal GABAergic interneuron activity drives hyperexcitability, amyloid pathology, and cognitive impairment in Alzheimer's disease (AD), suggesting that enhancing hippocampal inhibition may be protective. However, hippocampal interneurons are highly diverse and differentially regulate inhibition and cognition, making it challenging to identify the affected subtypes and optimally restore hippocampal inhibition in AD. We have previously found that Aβ selectively binds to two of the three major hippocampal nicotinic acetylcholine receptor (nAChR) subtypes, α7‐ and α4β2‐nAChRs, but not α3β4‐nAChRs, and inhibits these two receptors in hippocampal inhibitory interneurons to decrease their activity, leading to hyperexcitation in excitatory neurons. Here, we further reveal that α7‐ and α4β2‐nAChRs predominantly control nicotinic cholinergic signaling and neuronal activity in hippocampal parvalbumin‐positive (PV+) and somatostatin‐positive (SST+) inhibitory interneurons, respectively. We also find that systemic co‐stimulation of α7‐ and α4β2‐nAChRs is required to reverse hippocampal hyperexcitability, dysfunction of fear learning‐associated hippocampal oscillatory activity, and hippocampus‐dependent memory loss, and to reduce Aβ pathology in AD model mice. This suggests that co‐stimulation of PV+ and SST+ cells via activation of α7‐ and α4β2‐nAChRs together is required to enhance hippocampal inhibition optimally, which reverses hippocampal dysfunction, reduces amyloid pathology, and ultimately prevents memory loss in AD.
- 27 September 2026
- Published by Wiley in Advanced Science
- p. e77858
Open AccessCo‐activation of Selective Nicotinic Acetylcholine Receptor Subtypes Is Required for Neuroprotection against Alzheimer's Disease
Beta‐amyloid peptide (Aβ)‐induced suppression of hippocampal GABAergic interneuron activity drives hyperexcitability, amyloid pathology, and cognitive impairment in Alzheimer's disease (AD), suggesting that enhancing hippocampal inhibition may be protective. However, hippocampal interneurons are highly diverse and differentially regulate inhibition and cognition, making it challenging to identify the affected subtypes and optimally restore hippocampal inhibition in AD. We have previously found that Aβ selectively binds to two of the three major hippocampal nicotinic acetylcholine receptor (nAChR) subtypes, α7‐ and α4β2‐nAChRs, but not α3β4‐nAChRs, and inhibits these two receptors in hippocampal inhibitory interneurons to decrease their activity, leading to hyperexcitation in excitatory neurons. Here, we further reveal that α7‐ and α4β2‐nAChRs predominantly control nicotinic cholinergic signaling and neuronal activity in hippocampal parvalbumin‐positive (PV+) and somatostatin‐positive (SST+) inhibitory interneurons, respectively. We also find that systemic co‐stimulation of α7‐ and α4β2‐nAChRs is required to reverse hippocampal hyperexcitability, dysfunction of fear learning‐associated hippocampal oscillatory activity, and hippocampus‐dependent memory loss, and to reduce Aβ pathology in AD model mice. This suggests that co‐stimulation of PV+ and SST+ cells via activation of α7‐ and α4β2‐nAChRs together is required to enhance hippocampal inhibition optimally, which reverses hippocampal dysfunction, reduces amyloid pathology, and ultimately prevents memory loss in AD.
- 5 February 2026
- Published by Elsevier in Neuroscience
- Vol. 598, 63-71
δ-catenin haploinsufficiency is sufficient to alter behaviors and glutamatergic synapses in mice
- 5 February 2026
- Published by Elsevier in Neuroscience
- Vol. 598, 63-71
δ-catenin haploinsufficiency is sufficient to alter behaviors and glutamatergic synapses in mice
- Open Access
- 10 October 2025
- Published by Elsevier in Journal of Ginseng Research
- Vol. 50 (1) , 100905
American ginseng (Panax quinquefolius L.) extracts (G1899) reverse stress-induced behavioral abnormalities in mice
- 10 October 2025
- Published by Elsevier in Journal of Ginseng Research
- Vol. 50 (1) , 100905
Open AccessAmerican ginseng (Panax quinquefolius L.) extracts (G1899) reverse stress-induced behavioral abnormalities in mice
- Open Access
- 26 August 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (16) , e70891
Ketamine Reverses Chronic Stress‐Induced Behavioral Changes via the Expression of Ca 2+ ‐Permeable AMPA Receptors in Mice
Chronic stress affects brain functions, leading to the development of mental disorders like anxiety and depression, as well as cognitive decline and social dysfunction. Among many biological changes in chronically stressed brains, disruptions in AMPA Receptor (AMPAR)‐mediated synaptic transmission in the hippocampus are associated with stress responses. We have revealed that low‐dose ketamine rapidly induces the expression of GluA1‐containing, GluA2‐lacking Ca 2+ ‐Permeable AMPARs (CP‐AMPARs), which enhances glutamatergic synaptic strength in hippocampal neurons. Additionally, subanesthetic low‐dose ketamine decreases anxiety‐ and depression‐like behaviors in naïve animals. In addition to reducing depression, some research indicates that ketamine may have protective effects against chronic stress in both humans and animals. However, the role of CP‐AMPARs in the actions of ketamine's antistress effects is largely unknown. We use whole‐cell patch‐clamp recordings from CA1 pyramidal neurons in female and male hippocampal slices and multiple behavioral assays, including reciprocal social interaction, contextual fear conditioning, and tail suspension test. We demonstrate that low‐dose ketamine treatment reverses chronic restraint stress (CRS)‐induced social dysfunction, a loss of hippocampus‐dependent fear learning and memory, and depression‐like behavior in both female and male mice. Furthermore, we show that the ketamine‐induced antistress effects on these behaviors are dependent on CP‐AMPAR expression. Our findings suggest that subanesthetic low‐dose ketamine rapidly triggers the expression of CP‐AMPARs in the hippocampus, which induces antidepressant and antistress effects.
- 26 August 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (16) , e70891
Open AccessKetamine Reverses Chronic Stress‐Induced Behavioral Changes via the Expression of Ca 2+ ‐Permeable AMPA Receptors in Mice
Chronic stress affects brain functions, leading to the development of mental disorders like anxiety and depression, as well as cognitive decline and social dysfunction. Among many biological changes in chronically stressed brains, disruptions in AMPA Receptor (AMPAR)‐mediated synaptic transmission in the hippocampus are associated with stress responses. We have revealed that low‐dose ketamine rapidly induces the expression of GluA1‐containing, GluA2‐lacking Ca 2+ ‐Permeable AMPARs (CP‐AMPARs), which enhances glutamatergic synaptic strength in hippocampal neurons. Additionally, subanesthetic low‐dose ketamine decreases anxiety‐ and depression‐like behaviors in naïve animals. In addition to reducing depression, some research indicates that ketamine may have protective effects against chronic stress in both humans and animals. However, the role of CP‐AMPARs in the actions of ketamine's antistress effects is largely unknown. We use whole‐cell patch‐clamp recordings from CA1 pyramidal neurons in female and male hippocampal slices and multiple behavioral assays, including reciprocal social interaction, contextual fear conditioning, and tail suspension test. We demonstrate that low‐dose ketamine treatment reverses chronic restraint stress (CRS)‐induced social dysfunction, a loss of hippocampus‐dependent fear learning and memory, and depression‐like behavior in both female and male mice. Furthermore, we show that the ketamine‐induced antistress effects on these behaviors are dependent on CP‐AMPAR expression. Our findings suggest that subanesthetic low‐dose ketamine rapidly triggers the expression of CP‐AMPARs in the hippocampus, which induces antidepressant and antistress effects.
- Open Access
δ-catenin haploinsufficiency is sufficient to alter behaviors and glutamatergic synapses in mice
δ-catenin (also known as CTNND2) functions as an anchor for the glutamatergic AMPA receptor (AMPARs) to regulate synaptic activity in excitatory synapses. Alteration in the gene coding δ-catenin has been implicated in many neurological disorders. Some of these genetic alterations exhibit a profound loss of δ-catenin functions in excitatory synapses. We have shown that δ-catenin deficiency induced by the homozygous δ-catenin knockout (KO) and autism-associated missense glycine 34 to serine (G34S) mutation significantly alters AMPAR-mediated synaptic activity in cortical neurons and disrupts social behavior in mice. Importantly, many genetic disorders are caused by haploinsufficiency. Indeed, δ-catenin haploinsufficiency contributes to severe autism and learning disabilities in humans. However, previous studies have used only homozygous δ-catenin deficiency models. Therefore, it is important to examine the effects of δ-catenin haploinsufficiency on animals’ behaviors and excitatory synapses. Here, we use heterozygous δ-catenin KO and G34S mice as a δ-catenin haploinsufficiency model to examine this idea. Multiple behavioral assays, a social behavior test, contextual fear conditioning, and an open field test, reveal that both δ-catenin KO and G34S haploinsufficiency significantly disrupt animals’ social behavior and fear learning and memory. Interestingly, only KO haploinsufficiency mice show anxiety-like behavior. A biochemical assay using brain extracts demonstrates that δ-catenin haploinsufficiency significantly affects the levels of synaptic δ-catenin and AMPARs. Our findings thus suggest that δ-catenin haploinsufficiency affects animals’ behaviors via altering glutamatergic synaptic activity.
Open Accessδ-catenin haploinsufficiency is sufficient to alter behaviors and glutamatergic synapses in mice
δ-catenin (also known as CTNND2) functions as an anchor for the glutamatergic AMPA receptor (AMPARs) to regulate synaptic activity in excitatory synapses. Alteration in the gene coding δ-catenin has been implicated in many neurological disorders. Some of these genetic alterations exhibit a profound loss of δ-catenin functions in excitatory synapses. We have shown that δ-catenin deficiency induced by the homozygous δ-catenin knockout (KO) and autism-associated missense glycine 34 to serine (G34S) mutation significantly alters AMPAR-mediated synaptic activity in cortical neurons and disrupts social behavior in mice. Importantly, many genetic disorders are caused by haploinsufficiency. Indeed, δ-catenin haploinsufficiency contributes to severe autism and learning disabilities in humans. However, previous studies have used only homozygous δ-catenin deficiency models. Therefore, it is important to examine the effects of δ-catenin haploinsufficiency on animals’ behaviors and excitatory synapses. Here, we use heterozygous δ-catenin KO and G34S mice as a δ-catenin haploinsufficiency model to examine this idea. Multiple behavioral assays, a social behavior test, contextual fear conditioning, and an open field test, reveal that both δ-catenin KO and G34S haploinsufficiency significantly disrupt animals’ social behavior and fear learning and memory. Interestingly, only KO haploinsufficiency mice show anxiety-like behavior. A biochemical assay using brain extracts demonstrates that δ-catenin haploinsufficiency significantly affects the levels of synaptic δ-catenin and AMPARs. Our findings thus suggest that δ-catenin haploinsufficiency affects animals’ behaviors via altering glutamatergic synaptic activity.
- Open Access
American ginseng ( Panax quinquefolius L.) extracts (G1899) reverse stress-induced behavioral abnormalities in mice
Stress affects brain functions, which leads to the development of mental disorders like anxiety, depression, cognitive decline, and social dysfunction. There is increasing focus on the role of nutritional, herbal and nutraceutical compounds on mental and cognitive functioning. Interestingly, studies suggest that American ginseng ( Panax quinquefolius L.) extracts (G1899) improve cognition. We thus examined whether G1899 showed protective effects on stress-induced behavioral changes in animals. 200 mg/kg G1899 was orally administered daily for 4 weeks to 2-3-month-old female and male mice before inducing stress. To induce acute stress in animals, we intraperitoneally injected a low dose of lipopolysaccharides (LPS) (10 μg/kg), and saline was used as a control. We also used chronic restraint stress (CRS) as a chronic stress model in mice. After LPS injection or CRS, multiple behavioral assays were carried out – a sucrose preference test, an open filed test, reciprocal social interaction, contextual fear conditioning, and a tail suspension test – to determine whether acute or chronic stress affected animals’ behaviors and whether G1899 had protective effects against stress-induced behavioral dysfunction. We found that both LPS injection and CRS induced stress-related behavioral dysfunction, including depression-like behavior, anhedonia, social dysfunction, and fear memory impairments in both females and males. However, G1899 treatment was sufficient to reverse stress-induced behavioral abnormalities in animals. Our data further suggested that G1899 reduced the activity of hippocampal neurons by suppressing glutamatergic activity. Our study suggests that G1899 supplements can be protective against both acute and chronic stress in mice by suppressing neuronal and synaptic activity. Highlights: American ginseng ( Panax quinquefolius L.) extract (G1899) treatment reverses acute stress-induced behavioral dysfunction in mice. G1899 treatment reverses chronic stress-induced behavioral dysfunction in mice. G1899 treatment reduces serum corticosterone levels in chronically stressed mice. G1899 treatment suppresses glutamatergic activity in hippocampal neurons.
Open AccessAmerican ginseng ( Panax quinquefolius L.) extracts (G1899) reverse stress-induced behavioral abnormalities in mice
Stress affects brain functions, which leads to the development of mental disorders like anxiety, depression, cognitive decline, and social dysfunction. There is increasing focus on the role of nutritional, herbal and nutraceutical compounds on mental and cognitive functioning. Interestingly, studies suggest that American ginseng ( Panax quinquefolius L.) extracts (G1899) improve cognition. We thus examined whether G1899 showed protective effects on stress-induced behavioral changes in animals. 200 mg/kg G1899 was orally administered daily for 4 weeks to 2-3-month-old female and male mice before inducing stress. To induce acute stress in animals, we intraperitoneally injected a low dose of lipopolysaccharides (LPS) (10 μg/kg), and saline was used as a control. We also used chronic restraint stress (CRS) as a chronic stress model in mice. After LPS injection or CRS, multiple behavioral assays were carried out – a sucrose preference test, an open filed test, reciprocal social interaction, contextual fear conditioning, and a tail suspension test – to determine whether acute or chronic stress affected animals’ behaviors and whether G1899 had protective effects against stress-induced behavioral dysfunction. We found that both LPS injection and CRS induced stress-related behavioral dysfunction, including depression-like behavior, anhedonia, social dysfunction, and fear memory impairments in both females and males. However, G1899 treatment was sufficient to reverse stress-induced behavioral abnormalities in animals. Our data further suggested that G1899 reduced the activity of hippocampal neurons by suppressing glutamatergic activity. Our study suggests that G1899 supplements can be protective against both acute and chronic stress in mice by suppressing neuronal and synaptic activity. Highlights: American ginseng ( Panax quinquefolius L.) extract (G1899) treatment reverses acute stress-induced behavioral dysfunction in mice. G1899 treatment reverses chronic stress-induced behavioral dysfunction in mice. G1899 treatment reduces serum corticosterone levels in chronically stressed mice. G1899 treatment suppresses glutamatergic activity in hippocampal neurons.
- Open Access
Ketamine reverses chronic stress-induced behavioral changes via Ca 2+ -permeable AMPA receptors in mice
Background and Purpose: Chronic stress affects brain functions leading to the development of mental disorders like anxiety and depression, as well as cognitive decline and social dysfunction. Among many biological changes in chronically stressed brains, disruptions in AMPA Receptor (AMPAR)-mediated synaptic transmission in the hippocampus are associated with stress responses. We have revealed that low-dose ketamine rapidly induces the expression of GluA1-containing, GluA2-lacking Ca 2+ -Permeable AMPARs (CP-AMPARs), which enhances glutamatergic synaptic strength in hippocampal neurons. Additionally, subanesthetic low-dose ketamine decreases anxiety-and depression-like behaviors in naïve animals. In addition to reducing depression, some research indicates that ketamine may have protective effects against chronic stress in both humans and animals. However, the role of CP-AMPARs in the actions of ketamine’s antistress effects is largely unknown. Experimental Approach: We use whole-cell patch-clamp recordings from CA1 pyramidal neurons in female and male hippocampal slices and multiple behavioral assays including reciprocal social interaction, contextual fear conditioning, and tail suspension test. Key Results: We demonstrate that low-dose ketamine treatment reverses chronic restraint stress (CRS)-induced social dysfunction, hippocampus-dependent fear memory loss, and depression-like behavior in both female and male mice. Furthermore, we show that the ketamine-induced antistress effects on these behaviors are dependent on CP-AMPARs. Conclusion and Implications: Our findings suggest that subanesthetic low-dose ketamine rapidly triggers synaptic insertion of CP-AMPARs in the hippocampus, which induces antidepressant and antistress effects. What is already known: After demonstrating rapid and robust antidepressant efficacy, the US Food and Drug Administration (FDA) approved esketamine (the S enantiomer form of ketamine) for the treatment of depression in 2019, sparking a surge in clinical and public interest around the world. Although the exact mechanisms are largely unknown, one mechanism postulated for ketamine’s actions involves the enhancement of excitatory synaptic drive through an increase in AMPA receptor (AMPAR)-mediated synaptic activity. What this study adds: This study discovers that a single dose of ketamine rapidly (∼one hour) induces synaptic insertion of GluA1-containing, GluA2-lacking C a 2+ - P ermeable AMPAR s (CP-AMPARs), which is required for the antistress effects in animals. Clinical significance: Ketamine is typically given in just a single dose or short series of doses rather than repeated treatments because of potential misuse and addictive properties. Furthermore, rapid relapse of depression occurs after cessation of ketamine treatment (18 - 19 days post-infusion). Understanding the precise mechanisms behind ketamine’s antidepressant effects could lead to the development of new clinical approaches to overcome its primary therapeutic limitation of restricted patient use. Unfortunately, the potential sex differences in response to ketamine have been particularly understudied at this time although the hypersensitivity of females to ketamine’s effects at lower doses has been shown in several animals’ studies. Therefore, our findings may help develop tailored treatment and dosing in clinics.
Open AccessKetamine reverses chronic stress-induced behavioral changes via Ca 2+ -permeable AMPA receptors in mice
Background and Purpose: Chronic stress affects brain functions leading to the development of mental disorders like anxiety and depression, as well as cognitive decline and social dysfunction. Among many biological changes in chronically stressed brains, disruptions in AMPA Receptor (AMPAR)-mediated synaptic transmission in the hippocampus are associated with stress responses. We have revealed that low-dose ketamine rapidly induces the expression of GluA1-containing, GluA2-lacking Ca 2+ -Permeable AMPARs (CP-AMPARs), which enhances glutamatergic synaptic strength in hippocampal neurons. Additionally, subanesthetic low-dose ketamine decreases anxiety-and depression-like behaviors in naïve animals. In addition to reducing depression, some research indicates that ketamine may have protective effects against chronic stress in both humans and animals. However, the role of CP-AMPARs in the actions of ketamine’s antistress effects is largely unknown. Experimental Approach: We use whole-cell patch-clamp recordings from CA1 pyramidal neurons in female and male hippocampal slices and multiple behavioral assays including reciprocal social interaction, contextual fear conditioning, and tail suspension test. Key Results: We demonstrate that low-dose ketamine treatment reverses chronic restraint stress (CRS)-induced social dysfunction, hippocampus-dependent fear memory loss, and depression-like behavior in both female and male mice. Furthermore, we show that the ketamine-induced antistress effects on these behaviors are dependent on CP-AMPARs. Conclusion and Implications: Our findings suggest that subanesthetic low-dose ketamine rapidly triggers synaptic insertion of CP-AMPARs in the hippocampus, which induces antidepressant and antistress effects. What is already known: After demonstrating rapid and robust antidepressant efficacy, the US Food and Drug Administration (FDA) approved esketamine (the S enantiomer form of ketamine) for the treatment of depression in 2019, sparking a surge in clinical and public interest around the world. Although the exact mechanisms are largely unknown, one mechanism postulated for ketamine’s actions involves the enhancement of excitatory synaptic drive through an increase in AMPA receptor (AMPAR)-mediated synaptic activity. What this study adds: This study discovers that a single dose of ketamine rapidly (∼one hour) induces synaptic insertion of GluA1-containing, GluA2-lacking C a 2+ - P ermeable AMPAR s (CP-AMPARs), which is required for the antistress effects in animals. Clinical significance: Ketamine is typically given in just a single dose or short series of doses rather than repeated treatments because of potential misuse and addictive properties. Furthermore, rapid relapse of depression occurs after cessation of ketamine treatment (18 - 19 days post-infusion). Understanding the precise mechanisms behind ketamine’s antidepressant effects could lead to the development of new clinical approaches to overcome its primary therapeutic limitation of restricted patient use. Unfortunately, the potential sex differences in response to ketamine have been particularly understudied at this time although the hypersensitivity of females to ketamine’s effects at lower doses has been shown in several animals’ studies. Therefore, our findings may help develop tailored treatment and dosing in clinics.
- Open Access
Co-activation of selective nicotinic acetylcholine receptor subtypes is required for neuroprotection in Alzheimer’s disease
Alzheimer’s disease (AD) is characterized by hippocampal hyperexcitability and cognitive impairment, in part due to β-amyloid (Aβ)–induced suppression of GABAergic interneuron activity. Enhancing hippocampal inhibition is therefore considered protective, but inhibitory interneurons are highly diverse and not uniformly affected by Aβ. We previously showed that Aβ selectively inhibits α7- and α4β2-nicotinic acetylcholine receptors (nAChRs), but not α3β4-nAChRs, on hippocampal inhibitory interneurons, leading to excitatory neuron hyperactivity, and that co-activation of α7- and α4β2-nAChRs reverses these effects. Here, we demonstrate that α7- and α4β2-nAChRs predominantly regulate cholinergic synaptic activity in parvalbumin-positive (PV+) and somatostatin-positive (SST+) interneurons, respectively. Systemic co-stimulation of these receptors is required to reverse hippocampal hyperexcitability, fear learning-related oscillatory dysfunction, and fear memory loss, and reduce Aβ pathology in AD model mice, indicating that coordinated activation of PV+ and SST+ interneurons via co-activation of α7- and α4β2-nAChRs is required for optimal therapeutic benefit. Teaser: Co-activation of selective cholinergic receptors is required to protect Alzheimer’s disease.
Open AccessCo-activation of selective nicotinic acetylcholine receptor subtypes is required for neuroprotection in Alzheimer’s disease
Alzheimer’s disease (AD) is characterized by hippocampal hyperexcitability and cognitive impairment, in part due to β-amyloid (Aβ)–induced suppression of GABAergic interneuron activity. Enhancing hippocampal inhibition is therefore considered protective, but inhibitory interneurons are highly diverse and not uniformly affected by Aβ. We previously showed that Aβ selectively inhibits α7- and α4β2-nicotinic acetylcholine receptors (nAChRs), but not α3β4-nAChRs, on hippocampal inhibitory interneurons, leading to excitatory neuron hyperactivity, and that co-activation of α7- and α4β2-nAChRs reverses these effects. Here, we demonstrate that α7- and α4β2-nAChRs predominantly regulate cholinergic synaptic activity in parvalbumin-positive (PV+) and somatostatin-positive (SST+) interneurons, respectively. Systemic co-stimulation of these receptors is required to reverse hippocampal hyperexcitability, fear learning-related oscillatory dysfunction, and fear memory loss, and reduce Aβ pathology in AD model mice, indicating that coordinated activation of PV+ and SST+ interneurons via co-activation of α7- and α4β2-nAChRs is required for optimal therapeutic benefit. Teaser: Co-activation of selective cholinergic receptors is required to protect Alzheimer’s disease.
- 23 April 2024
- Published by Elsevier in Neuropharmacology
- Vol. 253, 109963
Prenatal exposure to valproic acid reduces synaptic δ-catenin levels and disrupts ultrasonic vocalization in neonates
- 23 April 2024
- Published by Elsevier in Neuropharmacology
- Vol. 253, 109963
Prenatal exposure to valproic acid reduces synaptic δ-catenin levels and disrupts ultrasonic vocalization in neonates
- Open Access
Prenatal exposure to valproic acid reduces synaptic δ-catenin levels and disrupts ultrasonic vocalization in neonates
Valproic acid (VPA) is an effective and commonly prescribed drug for epilepsy and bipolar disorder. However, children born from mothers treated with VPA during pregnancy exhibit an increased incidence of autism spectrum disorder (ASD). Although VPA may impair brain development at the cellular level, the mechanism of VPA-induced ASD has not been completely addressed. A previous study has found that VPA treatment strongly reduces δ-catenin mRNA levels in cultured human neurons. δ-catenin is important for the control of glutamatergic synapses and is strongly associated with ASD. VPA inhibits dendritic morphogenesis in developing neurons, an effect that is also found in neurons lacking δ-catenin expression. We thus hypothesize that prenatal exposure to VPA significantly reduces δ-catenin levels in the brain, which impairs glutamatergic synapses to cause ASD. Here, we found that prenatal exposure to VPA markedly reduced δ-catenin levels in the brain of mouse pups. VPA treatment also impaired dendritic branching in developing mouse cortical neurons, which was reversed by elevating δ-catenin expression. Prenatal VPA exposure significantly reduced synaptic AMPA receptor levels and postsynaptic density 95 (PSD95) in the brain of mouse pups, indicating dysfunctions in glutamatergic synaptic transmission. VPA exposure also significantly altered ultrasonic vocalization (USV) in newly born pups when they were isolated from their nest. Moreover, VPA-exposed pups show impaired hypothalamic response to isolation, which is required to produce animals’ USVs following isolation from the nest. Therefore, these results suggest that VPA-induced ASD pathology can be mediated by the loss of δ-catenin functions. Highlights: Prenatal exposure of valproic acid (VPA) in mice significantly reduces synaptic δ-catenin protein and AMPA receptor levels in the pups’ brains. VPA treatment significantly impairs dendritic branching in cultured cortical neurons, which is reversed by increased δ-catenin expression. VPA exposed pups exhibit impaired communication such as ultrasonic vocalization. Neuronal activation linked to ultrasonic vocalization is absent in VPA-exposed pups. The loss of δ-catenin functions underlies VPA-induced autism spectrum disorder (ASD) in early childhood.
Open AccessPrenatal exposure to valproic acid reduces synaptic δ-catenin levels and disrupts ultrasonic vocalization in neonates
Valproic acid (VPA) is an effective and commonly prescribed drug for epilepsy and bipolar disorder. However, children born from mothers treated with VPA during pregnancy exhibit an increased incidence of autism spectrum disorder (ASD). Although VPA may impair brain development at the cellular level, the mechanism of VPA-induced ASD has not been completely addressed. A previous study has found that VPA treatment strongly reduces δ-catenin mRNA levels in cultured human neurons. δ-catenin is important for the control of glutamatergic synapses and is strongly associated with ASD. VPA inhibits dendritic morphogenesis in developing neurons, an effect that is also found in neurons lacking δ-catenin expression. We thus hypothesize that prenatal exposure to VPA significantly reduces δ-catenin levels in the brain, which impairs glutamatergic synapses to cause ASD. Here, we found that prenatal exposure to VPA markedly reduced δ-catenin levels in the brain of mouse pups. VPA treatment also impaired dendritic branching in developing mouse cortical neurons, which was reversed by elevating δ-catenin expression. Prenatal VPA exposure significantly reduced synaptic AMPA receptor levels and postsynaptic density 95 (PSD95) in the brain of mouse pups, indicating dysfunctions in glutamatergic synaptic transmission. VPA exposure also significantly altered ultrasonic vocalization (USV) in newly born pups when they were isolated from their nest. Moreover, VPA-exposed pups show impaired hypothalamic response to isolation, which is required to produce animals’ USVs following isolation from the nest. Therefore, these results suggest that VPA-induced ASD pathology can be mediated by the loss of δ-catenin functions. Highlights: Prenatal exposure of valproic acid (VPA) in mice significantly reduces synaptic δ-catenin protein and AMPA receptor levels in the pups’ brains. VPA treatment significantly impairs dendritic branching in cultured cortical neurons, which is reversed by increased δ-catenin expression. VPA exposed pups exhibit impaired communication such as ultrasonic vocalization. Neuronal activation linked to ultrasonic vocalization is absent in VPA-exposed pups. The loss of δ-catenin functions underlies VPA-induced autism spectrum disorder (ASD) in early childhood.